Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: An analysis of 29 patients

Ikeda, Seiyo; Maeshiro, Kensei; Ryu, Shinichiro; Ogata, Kenji; Yasunami, Yohichi; Nakayama, Yoshihito; Hamada, Yusuke

doi:10.2958/suizo.24.635

Cited by 5 publications

(14 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pancreatic cancer is associated with a fast progression and a poor prognosis, and has an increasing incidence. Early diagnosis of pancreatic carcinoma is currently difficult, and the majority of patients are not diagnosed until an advanced stage (3,4). Furthermore, pancreatic cancer is highly resistant to apoptosis-inducing therapy, such as chemotherapy (5).…”

Section: Introductionmentioning

confidence: 99%

Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway

Liu

Jin

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Gemcitabine is a first‑line chemotherapeutic agent used in the treatment of pancreatic cancer; however resistance of the disease to the drug often develops over time. Agents that can either enhance the effects of gemcitabine, or help to overcome the chemoresistance to the drug are needed for the successful treatment of pancreatic cancer. Oridonin is one such agent which is safe and multi‑targeted and has previously been shown to induce apoptosis in other tumor cells, through mitochondrial signaling pathways. The aims of the present study were to evaluate whether oridonin may enhance the effects of gemcitabine on pancreatic cancer in vitro and to investigate the possible mechanisms of this enhancement. In vitro studies have previously shown that oridonin can inhibit the proliferation of the Panc‑1 pancreatic cancer cell line, and potentiate gemcitabine‑induced apoptosis, which was shown to be associated with cell cycle arrest in the G1 phase. Western blot and quantitative polymerase chain reaction analyses demonstrated that the expression levels of the anti‑apoptotic gene Bcl‑2 and the Bcl‑2/Bax ratio in the oridonin and the oridonin plus gemcitabine groups were significantly downregulated as compared with the gemcitabine treatment and control groups. The expression levels of pro‑apoptotic genes Bax, cytochrome c (cyt c), and caspase‑3 and ‑9 in the oridonin and the combination groups were significantly upregulated as compared with the other two groups. The results suggested that oridonin improved the anti‑tumor effects of gemcitabine through the enhancement of gemcitabine‑induced apoptosis.This mechanism may be through the downregulation of Bcl‑2 expression and the upregulation of Bax expression, resulting in the reduction of the Bcl‑2/Bax ratio. These effects may promote the release of cyt c from the mitochondria into the cytoplasm thus triggering the mitochondrial apoptosis signaling pathway. Furthermore, caspase‑3 and ‑9 were shown to be activated as a result of the induction of apoptosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway

Liu

Jin

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…So while some prefer to solicit the use of EUS-FNA for patients with resectable neoplasm or long-distance metastatic disease, others opt for the use of EUS-FNA as a neoadjuvant treatment in cases of resectable neoplasm. As previously mentioned, our study spans a 10-year period, and prior to the installation of EUS-FNA technology, our hospital used other histopathological methods in order to confirm the presence of an adenocarcinoma, such as laparoscopy or a cytology obtained by endoscopic retrograde cholangiopancreatography (ERCP); indeed, this is a recognized diagnostic method [28], and even today some medical authors still reclaim [29] its return and use with balloon during pancreatography.…”

Section: Survival Functionsmentioning

confidence: 99%

The Global Impact of Endoscopic Ultrasound (EUS) Regarding the Survival of a Pancreatic Adenocarcinoma in a Tertiary Hospital

Ulla-Rocha

Alvarez-Prechous

Paz-Esquete

et al. 2010

J Gastrointest Canc

View full text Add to dashboard Cite

show abstract

“…The majority of pancreatic carcinoma are in an advanced stage at the time of diagnosis, as early diagnosis of pancreatic carcinoma is still difficult (Ikeda et al, 2009). Unfortunately, the curative effect of advanced pancreatic carcinoma is very poor.…”

Section: Discussionmentioning

confidence: 99%

“…Early diagnosis of pancreatic carcinoma is still difficult, the majority patients with pancreatic carcinoma are in an advanced stage at the time of diagnosis (Ikeda et al,2009;Klauss et al, 2012;Zhou et al, 2012). Chemotherapy is one of the most important therapeutic methods in the treatment of pancreatic carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Continuous Transarterial Infusion Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Carcinoma

Hong

Zhou²,

Sun³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The objective effective rate in transarterial group was 33.3% versus 25% in the systemic group, the difference not being significant (P=0.626). Clinical benefit rates(CBR) in the transarterial and systemic groups were 83.3% and 58.3%, respectively (P=0.014). The means and medians for survival time in transarterial group were higher than those of the systemic group (P < 0.005). at the same time, the adverse effects did not significantly differ between the two groups (P > 0.05). Conclusion: Continuous transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil could improve clinical benefit rate and survival time of patients with advanced pancreatic carcinoma, compared with systemic venous chemotherapy. Since adverse effects were limited in the transarterial group, the regimen of continuous transarterial infusion chemotherapy can be used more extensively in clinical practice. A CT and MRI conventional sequence can be used for efficacy evaluation after chemotherapy in pancreatic carcinoma.

show abstract

Diagnosis of small pancreatic cancer by endoscopic balloon-catheter spot pancreatography: An analysis of 29 patients

Cited by 5 publications

References 1 publication

Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway

Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway

The Global Impact of Endoscopic Ultrasound (EUS) Regarding the Survival of a Pancreatic Adenocarcinoma in a Tertiary Hospital

Continuous Transarterial Infusion Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Carcinoma

Contact Info

Product

Resources

About